From inflation to interest rates, navigating the waters of a sea of global economic uncertainty and confusion, last week was full of tough questions for investors on the Bullboards.
We saw some of the most popular companies among our communities stuffer setbacks, while other smallcaps gained attention as investors looked for new potential plays.
Major swings and emerging opportunities alike often interest Bullboard users, so tapping into this community can show us what’s captivating value-seeking investors. This week, we highlight three plays in three sectors that drew a lot of attention.
First, we look at gold prices, which have struggled to hold on to its values since this spring, falling from its record highs seen only a few months ago, but miners in this space continue to unearth riches.
Wallbridge Mining Company (TSX:WM, Forum) is reporting positive assay results stemming from ongoing drilling at its Fenelon Gold Project.
The Ontario-based mineral exploration company further expanded the lateral footprint of the existing deposit at the project. This pushes it beyond the maiden Mineral Resources Estimate in 2021. Assay results are from 22 completed drill holes.
The project is located 80 kilometres east of Agnico Eagle’s Detour Lake gold mine at the centre of Wallbridge’s land package, which covers roughly 910 square kilometres of the most prospective ground on the Detour-Fenelon Gold Trend.
Though its stock has been trending downward this year, SNC-Lavalin Group (TSX:SNC, Forum) saw a recent boost both in the public market place, and at its headquarters. The company has been awarded a contract to provide services for the Georgia Department of Transportation (GDOT).
These include general engineering consulting and construction engineering and inspection services.
As prime consultant, SNC will provide services to GDOT’s Office of Alternative Delivery for up to five years under an Indefinite Delivery Indefinite Quantity contract that should not exceed $60 million.
Technical support will include assisting in the implementation of design-build projects located in the northeast region of the state.
SNC company, Candu Energy, had also made news earlier this week when it announced that it had been selected to provide design and engineering services for the Unit 1 CANDU reactor for $64 million.
As part of the 2.5-year contract, SNC-Lavalin stated it will provide engineering and early procurement services for retubing work to replace certain components of the reactor core allowing reactor’s operating life to extend until 2060. According to SNC-Lavalin, the reactor supplies 10 per cent of Romania’s electricity.
Looking at news in the health care space, Spectral Medical (TSX:EDT, Forum) updated its clinical trial of Tigris.
Spectral is a Phase 3 company seeking U.S. FDA approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream.
The clinical trial evaluated the use of Polymyxin B Hemoperfusion (PMX) on adults treated for endotoxemia and septic shock.
Spectral’s Chief Medical Officer Dr. John Kellum added that the trial site at the University of Michigan has randomized its first patient.
“The clinical staff at U of M witnessed immediate improvement in the patient’s status following administration of PMX and the patient was able to transfer out of the intensive care unit (ICU) sooner than expected. We believe this positive patient outcome, and the fact that data thus far is exceeding expectations, reinforces our prior EUPHRATES trial data and our overall confidence in the efficacy of PMX in this patient population.”
A Professor and Emergency Medicine Director at the Emergency Critical Care Center within the University of Michigan, Kyle Gunnerson, MD, FCCM, further noted that the patient saw rapid improvement and recovery following administration of PMX and was transferred out of the ICU sooner than anticipated.
This is a follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, with an end point being a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.
July has given us a wild market ride and some small-cap stocks that the Bullboards have gotten excited about. Next week will likely bring us more of the same, and the weekly Buzz on the Bullboards review will be here to bring you some intriguing stock highlights.
